 |
|
|
| |
Early Safety, Tolerability and Pharmacokinetic Profile of GSK2838232,
a Novel 2nd Generation HIV Maturation Inhibitor, as Assessed in
Healthy Subjects
|
| |
| |
Reported by Jules Levin
18th International Workshop on Clinical Pharmacology of Antiviral Therapy
June 14th-16th, Chicago
1,7Johnson, M; 1Jewell RC; 2Peppercorn, A; 1 Gould E; 3Xu, J; 1,4Lou, Y; 5Davies, M; 6Baldwin, S; 1,7Tenorio, A; 8Burke, M and 1Johns, B
1GSK, RTP, NC; 2GSK, Cambridge, MA; 3GSK, Collegeville, PA; 4Parexel, RTP, NC; 5GSK Stockley Park, UK; 6GSK Ware, UK; 7ViiV Healthcare, RTP, NC; 8GSK King of Prussia, PA
|
| |
|
|
|
|
|
